Open Access Highly Accessed Research article

Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study

Dong Min Cha1, Tae Wan Kim23*, Jang Won Heo2, Se Joon Woo4, Kyu Hyung Park4, Hyeong Gon Yu2 and Hum Chung2

Author Affiliations

1 Department of Ophthalmology, Jeju National University College of Medicine, Jeju, Korea

2 Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea

3 Department of Ophthalmology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, #395 Shindaebang-2-dong, Dongjak-gu, Seoul 156-707, Korea

4 Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Korea

For all author emails, please log on.

BMC Ophthalmology 2014, 14:69  doi:10.1186/1471-2415-14-69

Published: 21 May 2014

Abstract

Background

To compare the long-term efficacy of ranibizumab versus bevacizumab for myopic choroidal neovascularization (CNV).

Methods

This was a retrospective, multicenter, comparative, non-randomized study of 64 consecutive patients with myopic CNV treated with ranibizumab (22 patients) or bevacizumab (42 patients). Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography were evaluated before and after treatment. All the patients were followed for at least 12 months.

Results

BCVA (logarithm of the minimal angle of resolution) improved from 0.63 ± 0.30 to 0.43 ± 0.27, 0.41 ± 0.37, 0.40 ± 0.39, 0.39 ± 0.43, and 0.39 ± 0.42 at 1, 2, 3, 6, and 12 months after treatment in the ranibizumab group, and from 0.67 ± 0.28 to 0.52 ± 0.31, 0.49 ± 0.31, 0.47 ± 0.31, 0.42 ± 0.32, and 0.46 ± 0.43 in the bevacizumab group (all P < 0.05 compared with baseline BCVA in each group). CFT decreased by 20.21%, 19.58%, and 22.43% from the baseline 304 ± 76 μm at 3, 6, and 12 months after treatment in the former group, and by 15.20%, 15.67%, and 15.56% from the baseline 297 ± 62 μm in the latter group (all P < 0.05 compared with baseline CFT in each group). BCVA improvement and CFT reduction did not statistically differ when compared at the same periods from treatment between 2 groups. Neither ocular nor systemic safety problems appeared during follow up.

Conclusions

This study showed a similar functional and anatomical improvement after treatment of ranibizumab and bevacizumab for myopic CNV over a 12-month follow-up period.

Keywords:
Anti-VEGF (vascular endothelial growth factor); Bevacizumab; Myopic choroidal neovascularization; Ranibizumab